Mankind Pharma Key Ratios

NSE: MANKIND | BSE: 543904

₹2,382.90

up-down-arrow-34.60 (-1.43%)

As on 28-Aug-2026IST

Market cap

info icon

₹98,599 Cr

Revenue (TTM)

info icon

₹14,738 Cr

P/E Ratio

info icon

48.3

P/B Ratio

info icon

5.9

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 17.07 12.89 14.16 17.23 18.10
EBIT 17.50 32.22 19.45 18.48 12.33
Net Profit -1.02 29.60 13.50 13.32 8.43
EPS 2.42 29.51 6.75 10.32 7.97
Book Value -- -- 13.69 28.49 27.28
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 23.0820.2219.9119.1619.65
Net Margin info 18.7116.0713.6413.2415.75
Return on equity info 16.0019.7613.6012.6916.98
Return on Capital info 18.2123.47--13.2418.32
Return on Assets info 11.6313.587.367.0010.15
Debt to Equity (x) info ----0.170.370.58
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
--
13.24
18.32
28.35
23.49
Peer Median
--
19.34
21.76
21.89
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

13.60

Lower than Peers by 1.75

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
13.60
12.69
16.98
23.14
19.27
Peer Median
15.35
16.97
17.93
16.42
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

7.36

Lower than Peers by 2.99

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
7.36
7.00
10.15
18.00
13.94
Peer Median
10.35
9.88
12.81
12.32
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

19.91

Higher than Peers by 1.90

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
19.91
19.16
19.65
20.83
18.01
Peer Median
18.01
18.96
18.93
21.05
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

13.64

Lower than Peers by 0.81

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
13.64
13.24
15.75
18.41
14.75
Peer Median
14.45
13.29
14.94
15.51
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
--
18.91
20.73
21.72
17.96
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

14.16

Higher than Peers by 2.21

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
14.16
16.96
18.98
17.27
12.44
Peer Median
11.95
12.97
10.90
13.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

19.45

Lower than Peers by 2.15

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
19.45
14.04
12.29
35.58
-13.59
Peer Median
21.60
15.05
15.01
23.50
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

13.50

Lower than Peers by 9.24

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
13.50
-3.41
3.39
48.19
-9.86
Peer Median
22.73
11.89
14.80
30.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

6.75

Lower than Peers by 13.28

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
6.75
-3.97
1.05
49.22
-10.58
Peer Median
20.03
12.16
14.27
29.02
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
--
13.74
52.99
25.62
20.79
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

0.17

Higher than Peers by 0.17

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
0.17
0.37
0.58
0.02
0.02
Peer Median
0.00
0.05
0.06
0.03
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
--
0.04
0.18
0.02
0.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.07

Lower than Peers by 1.01

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
1.07
1.07
1.23
3.10
2.32
Peer Median
2.08
1.93
1.90
2.23
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.74

Lower than Peers by 0.80

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
0.74
0.74
0.86
2.36
1.52
Peer Median
1.54
1.52
1.46
1.59
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

5.41

Lower than Peers by 13.97

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
5.41
4.62
6.83
71.03
37.52
Peer Median
19.38
19.95
24.96
45.29
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

11.74

Lower than Peers by 9.65

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
11.74
12.11
12.60
8.27
6.59
Peer Median
21.38
19.87
21.77
20.10
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.53

Lower than Peers by 0.19

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
0.53
0.54
0.64
0.99
0.97
Peer Median
0.72
0.77
0.76
0.81
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
--
39.93
34.35
24.35
19.33
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
--
51.78
52.50
52.16
65.31
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
--
111.46
99.93
101.86
130.57
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
--
-19.75
-13.08
-25.35
-45.92
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

48.27

Higher than Peers by 14.28

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
48.27
43.29
50.22
48.11
--
Peer Median
33.99
34.30
26.81
39.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

5.86

Higher than Peers by 0.80

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
5.86
5.09
7.00
9.85
--
Peer Median
5.06
5.19
4.65
6.11
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

0.04

Lower than Peers by 0.45

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
0.04
0.05
--
--
--
Peer Median
0.49
0.50
0.61
0.37
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

25.09

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
25.09
22.19
30.28
32.74
-0.12
Peer Median
--
30.46
27.02
34.57
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

98,599

Higher than Peers by 79,473

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Mankind Pharma
98,599
82,802
99,979
92,032
--
Peer Median
19,125
18,009
20,914
25,297
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...